Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PIRMELLA 1/35 vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: June 2026 · OpiCalc Medical Review Team
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that suppresses gonadotropin secretion via negative feedback on the hypothalamic-pituitary-ovarian axis, inhibiting ovulation. Additionally, causes cervical mucus thickening and endometrial atrophy, reducing sperm penetration and implantation.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Prevention of pregnancy
Prevention of pregnancy
One tablet orally once daily for 21 days, followed by 7 placebo tablets during the withdrawal bleed.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Terminal half-life 24–30 hours for ethinyl estradiol; 13–18 hours for norethindrone. Steady state reached after 7–10 days.
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Norethindrone: primarily via CYP3A4 to conjugated metabolites; ethinyl estradiol: primarily via CYP3A4 and sulfation (SULT1E1) with enterohepatic circulation.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment (GFR <30 m L/min) due to potential fluid retention and hypertension.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Cigarette smoking increases risk of serious cardiovascular events (thrombosis, myocardial infarction, stroke). Risk increases with age and smoking intensity, especially in women over 35 years who smoke. COCs should not be used by women over 35 who smoke.
First trimester: Norethindrone and ethinyl estradiol carry a known risk of teratogenicity, including cardiovascular defects and limb reduction defects, with an estimated relative risk of 1.3-1.4 for major malformations. Second and third trimesters: Exposure may lead to feminization of male fetuses (norethindrone) and potential adverse effects on fetal neurodevelopment; risk of intrauterine growth restriction and preterm delivery increased with high-dose estrogen. Postnatal effects include vaginal adenosis and clear cell adenocarcinoma in females exposed in utero to diethylstilbestrol, but data for this combination are limited. Overall, contraindicated in pregnancy due to known risks.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
Combination oral contraceptive containing 1mg norethindrone and 35mcg ethinyl estradiol. Prescribe for contraception, dysmenorrhea, or menstrual regulation. Counsel patients to take at the same time daily to maintain hormone levels and reduce risk of breakthrough bleeding. Monitor blood pressure at baseline and annually due to estrogen component. Consider alternative contraception in women with migraine with aura, uncontrolled hypertension, or history of thromboembolism. Smoking cessation strongly advised in patients over 35 due to increased thrombotic risk.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
No interactions on record
No interactions on record
Common clinical questions about PIRMELLA 1/35 vs ALYACEN 1/35, answered by our medical review team.
PIRMELLA 1/35 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that suppresses gonadotropin secretion via negative feedback on the hypothalamic-pituitary-ovarian axis, inhibiting ovulation. Additionally, causes cervical mucus thickening and endometrial atrophy, reducing sperm penetration and implantation.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PIRMELLA 1/35 and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PIRMELLA 1/35 is: One tablet orally once daily for 21 days, followed by 7 placebo tablets during the withdrawal bleed.. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PIRMELLA 1/35 and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PIRMELLA 1/35 is classified as Category C. First trimester: Norethindrone and ethinyl estradiol carry a known risk of teratogenicity, including cardiovascular defects and limb reduction defects, with an estimated relative r. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Renal 60–80% as metabolites (glucuronide conjugates), biliary/fecal 10–20%.
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
Ethinyl estradiol: 97–98% bound to albumin and SHBG; norethindrone: 80–85% bound to SHBG and albumin.
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
Ethinyl estradiol: 4.0–4.5 L/kg; norethindrone: 3.5–4.0 L/kg. Indicates extensive tissue distribution.
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral: ethinyl estradiol ~45% (first-pass metabolism); norethindrone ~65%.
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
Contraindicated in Child-Pugh class B and C (moderate to severe hepatic impairment). In Child-Pugh class A, use with caution and consider alternative contraception.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Not indicated for use before menarche; after menarche, dosing is same as adult: one tablet orally once daily for 21 days followed by 7 placebo tablets.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
Not indicated for use in postmenopausal women. No specific dose adjustment in elderly if still menstruating, but consider increased risk of thromboembolism and cardiovascular events.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
No significant food interactions. Grapefruit juice may slightly increase estrogen levels but not clinically significant. Consistent dietary habits recommended to avoid gastrointestinal upset; taking with food can reduce nausea. No restrictions with alcohol, but excessive intake may impair liver function affecting hormone metabolism.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
Norethindrone and ethinyl estradiol are excreted into breast milk in small amounts; the M/P ratio for ethinyl estradiol is approximately 0.4-0.6. May reduce milk production and volume, particularly in early lactation. Breastfeeding is not recommended, especially during the first 6 months postpartum. Consider progestin-only contraceptives as alternatives.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
No dosing adjustment is applicable as this drug is contraindicated in pregnancy. If inadvertently taken, discontinue immediately. No pharmacokinetic dose adjustments are recommended because use is contraindicated.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
Take one tablet daily at the same time, preferably after a meal to reduce nausea.,If you miss a pill, follow the package instructions or consult your healthcare provider; use backup contraception for 7 days.,Common side effects include nausea, breast tenderness, and spotting, which often improve within a few cycles.,Report symptoms of blood clots: sudden leg pain/swelling, chest pain, shortness of breath, or severe headache.,This medication does not protect against sexually transmitted infections; use condoms for STI prevention.,If you are a smoker and over 35, discuss smoking cessation due to increased risk of serious cardiovascular events.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.